Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986171
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
BMS-986171 is a subcutaneously administered pegylated variant of fibroblast growth factor 21 (FGF21) developed by Bristol Myers Squibb. It acts as a fibroblast growth factor replacement and is classified as an antifibrotic, fibroblast growth factor, and hepatoprotectant. The drug was primarily investigated for the treatment of non-alcoholic steatohepatitis (NASH) and hepatic fibrosis. Preclinical studies in animal models demonstrated that BMS-986171 improved liver steatosis and fibrosis, supporting its therapeutic potential in NASH. However, no recent clinical development has been reported beyond early-phase trials[1][5][7].
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on BMS-986171.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986171.